| 2.375 0.035 (1.5%) | 12-08 12:10 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.14 |
1-year : | 3.62 |
| Resists | First : | 2.69 |
Second : | 3.09 |
| Pivot price | 2.26 |
|||
| Supports | First : | 2.03 | Second : | 1.69 |
| MAs | MA(5) : | 2.39  |
MA(20) : | 2.33 |
| MA(100) : | 2.67 |
MA(250) : | 0 | |
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 61.5 |
D(3) : | 59 |
| RSI | RSI(14): 45.5 | |||
| 52-week | High : | 7.13 | Low : | 0.46 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ PROK ] has closed below upper band by 34.8%. Bollinger Bands are 55.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.65 - 2.67 | 2.67 - 2.68 |
| Low: | 2.29 - 2.3 | 2.3 - 2.32 |
| Close: | 2.32 - 2.34 | 2.34 - 2.36 |
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Sat, 06 Dec 2025
ProKidney (NASDAQ:PROK) Trading Down 6.8% - What's Next? - MarketBeat
Sun, 23 Nov 2025
While insiders own 18% of ProKidney Corp. (NASDAQ:PROK), retail investors are its largest shareholders with 50% ownership - Yahoo Finance
Mon, 10 Nov 2025
ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates - GlobeNewswire
Thu, 06 Nov 2025
ProKidney Corp. Reports Positive Phase 2 Results for Rilparencel in Advanced Chronic Kidney Disease and Diabetes - Quiver Quantitative
Mon, 20 Oct 2025
Late‑Breaking Phase 2 REGEN‑007 Results: ProKidney to Present Two Posters at ASN Kidney Week Nov 6 - Stock Titan
Fri, 19 Sep 2025
ProKidney: Slow-Burning 'Buy' Opportunity Based On 2027 Approval Of Kidney Disease Therapy - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 142 (M) |
| Held by Insiders | 9.327e+007 (%) |
| Held by Institutions | 25.3 (%) |
| Shares Short | 10,740 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.6458e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -17 % |
| Return on Assets (ttm) | 613.3 % |
| Return on Equity (ttm) | -25.9 % |
| Qtrly Rev. Growth | 744000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -23.23 |
| EBITDA (p.s.) | 413333 |
| Qtrly Earnings Growth | -0.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -112 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.11 |
| Price to Cash Flow | -0.57 |
| Dividend | 0 |
| Forward Dividend | 1.396e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|